A Summary of the Evidence Relating Postmenopausal Hormone Use and Large Bowel Cancer Risk

  • Polly A. Newcomb
Part of the Medical Science Symposia Series book series (MSSS, volume 13)


Colorectal cancer is second only to lung cancer as the leading cause of cancer mortality and remains a significant cause of morbidity. Increasing evidence indicates that postmenopausal hormone replacement (HRT) use may significantly decrease the risk of colorectal cancer in women. This report summarizes the epidemiologic and biologic support for a link between estrogens and large bowel cancer.


Colorectal Cancer Bile Acid Hormone Replacement Therapy Colon Carcinogenesis Colorectal Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ries LAG, Kosary CL, Hankey BF, Harras A, Miller BA, Edwards BK, editors. SEER Cancer Statistics Review, 1973–1993: Tables and Graphs. Bethesda, MD: National Cancer Institute, 1996.Google Scholar
  2. 2.
    McMichael AJ, Potter JD, Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks for bowel cancer and other biliary and intestinal diseases? Am J Epidemiol 1983;118:620–27.PubMedGoogle Scholar
  3. 3.
    Potter JD. Editorial: Hormones and Colon Cancer. J Natl Cancer Inst 1995;87:1039–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: A review of the epidemiology. Epi Rev 1993;15:499–545.Google Scholar
  5. 5.
    McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: A review and hypothesis. J Natl Cancer Inst 1980;65:1201–7.PubMedGoogle Scholar
  6. 6.
    Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use and risk of colorectal cancer. Cancer Epidemiol Biomarkers 1977;6:1–5.Google Scholar
  7. 7.
    Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: A case-control study. J Nat Cancer Inst 1983;71:703–9.PubMedGoogle Scholar
  8. 8.
    Fernandez E, LaVecchia C, Francheschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;9:295–300.PubMedCrossRefGoogle Scholar
  9. 9.
    Calle EE. Hormone replacement therapy and colorectal cancer: Interpreting the evidence. Cancer Causes Control 1997;8:127–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981;67:57–60.PubMedGoogle Scholar
  11. 11.
    Peters RK, Pike MC, Chang WWL, Mack TM. Reproductive factors and colon cancers. Br J Cancer 1990;61:741–48.PubMedGoogle Scholar
  12. 12.
    Davis FG, Furner SE, Persky V, Koch M. The influence of parity and exogenous female hormones on the risk of colorectal cancer. Int J Cancer 1989;43:587–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large bowel cancer. J Natl Cancer Inst 1995;87:1067–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control 1994;5:359–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Furner SE, Davis FG, Nelson RL, Haenszel W. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 1989;49:4936–40.PubMedGoogle Scholar
  16. 16.
    Kampman E, Potter JD, Slattery ML, et al. Hormone replacement therapy, reproductive history and colon cancer. Cancer Causes Control 1997;8:146–58.PubMedCrossRefGoogle Scholar
  17. 17.
    Gerhardsson de Verdier M, London S. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 1992;3:355–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Fernandez E, La Vecchia C, D’Avanzo B, et al. Oral contraceptives, hormone replacement therapy and risk of colorectal cancer. Br J Cancer 1996;73:1431–35.PubMedGoogle Scholar
  19. 19.
    Grodstein F, Martinez ME, Giovannucci EL, et al. Postmenopausai hormone use and colorectal cancer in the Nurses’ Health Study. Ann Int Med 1998;128:705–12.PubMedGoogle Scholar
  20. 20.
    Folsom AR, Mink JJ, Sellers TA, et al. Hormone replacement therapy and morbidity and mortality in a prospective study of postmenopausai women. Am J Public Health 1995;85:1128–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Persson I, Yven J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and progestin therapy. Int J Cancer 1996;67:327–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausai women. J Natl Cancer Inst 1995;87:517–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Sturgeon SK, Schairer C, Brinton LA, et al. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6:227–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: A record linkage cohort study. Cancer Epidemiol Biomarkers Prev 1995;4:21–28.PubMedGoogle Scholar
  25. 25.
    Troisi R, Schairer C, Chow WH, et al. Reproductive factors, oral contraceptive use and risk of colorectal cancer in the United States. Epidemiology 1997;8:75–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. Br J Cancer 1987;55:687–94.PubMedGoogle Scholar
  27. 27.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Pepins LA, Newman B, Sandher RS. Reproductive history, use of exogenous hormones and risk of adenomatous polyps. Cancer Epidemiology Biomarkers Prev 1997;6:671–75.Google Scholar
  29. 29.
    Potter JD, Bostick RM, Grandits GH, et al. Hormone replacement therapy is associated with a lower risk of adenometous polyps of the large bowel. Cancer Epidemiol Biomarkers Prev 1996;5:779–84.PubMedGoogle Scholar
  30. 30.
    Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy are users healthier than non-users? Am J Epidemiol 1996;143:971–78.PubMedGoogle Scholar
  31. 31.
    Barrett-Connor E. Postmenopausai estrogen and prevention bias. Ann Intern Med 1991;115:455–56.PubMedGoogle Scholar
  32. 32.
    Schairer C, Adami HO, Hoover R, Persson I. Case-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59–65.PubMedCrossRefGoogle Scholar
  33. 33.
    U.S. Preventive Services Task Force. Report. Guide to Clinical Preventive Services Screening for Colorectal Cancer. Baltimore: Williams and Wilkins, 1996:89–104.Google Scholar
  34. 34.
    Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study. J NatI Cancer 1995;87:645–51.Google Scholar
  35. 35.
    Newcomb PA, Solomon C, White E. Tamoxifin and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat, in press.Google Scholar
  36. 36.
    Reddy BS, Watanabe K, Weisburger JH, Wynder EL. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res 1977;37:2533–39.Google Scholar
  37. 37.
    McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:687–95.PubMedGoogle Scholar
  38. 38.
    Di Leo A, Messa C, Russo F, et al. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Digestive Diseases and Science 1994;39:2038–42.CrossRefGoogle Scholar
  39. 39.
    Trentham-Dietz A, Newcomb PA, Gilchrist K. Hormone replacement therapy and risk of postmenopausal breast cancer according to estrogen and progesterone receptor status. Proc Amer Assoc Cancer Res 1998;39:101.Google Scholar
  40. 40.
    Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Lointer P, Wildrick DU, Boman N. The effects of steroid hormones on human cancer cell lining in vitro. Anti Cancer Research 1992;12:1327–30.Google Scholar
  42. 42.
    Hoff MB, Chang WWL. The effect of estrogen on epithelial cell proliferation and differentiation in the crypts of the descending colon of the mouse: A radioautographic study. Am J Anat 1979;155:507–16.PubMedCrossRefGoogle Scholar
  43. 43.
    Tutton PJM, Barkla DH. Differential effects of estrogenic hormones on cell proliferation in the epithelium and colonie carcinomata of rats. Anticancer Res 1982;2:199–202.PubMedGoogle Scholar
  44. 44.
    Issa J-P, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the estrogen receptor CpG island links aging and neoplasia in human colon. Nature Genetics 1994;7:536–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279–83.PubMedGoogle Scholar
  46. 46.
    Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619–28.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • Polly A. Newcomb

There are no affiliations available

Personalised recommendations